资源描述：
《4种含顺铂化疗方案治疗晚期非小细胞肺癌疗效及费用对比分析》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、中国预防医学杂志2009年7月第10卷第7期ChinPrevMed,July2009,Vol10No7595论著4种含顺铂化疗方案治疗晚期非小细胞肺癌疗效及费用对比分析王海永,潘习龙摘要目的比较4种含顺铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效及费用关系。方法153例晚期NSCLC病例分成4组:TP组(紫杉醇、顺铂)36例,GP组(健泽、顺铂)39例,NP组(长春瑞宾、顺铂)51例;MVP组(丝裂霉素、长春地辛、顺铂)27例。回顾性分析各组的近期疗效,并采用药物经济学的
2、成本-效果分析法进行评价。结果TP组、NP组、GP组和MVP组近期有效率为278%、294%、333%和222%(P>005);肿瘤控制率为750%、686%、897%和556%(P<005);平均成本为332043元、206083元、274390元和120249元;C/E有效率为11944、7042、8239和5416;C/E肿瘤控制率4427、3018、3060和2163。结论4种以顺铂为基础的化疗方案对晚期NSCLC均有一定的疗效,GP方案在肿瘤控
3、制和毒副反应方面有优势,NP方案在费用控制方面占优势。建议经济条件较好、尤其是老年晚期NSCLC患者使用GP方案;对于年龄较轻、化疗耐受性较好,而经济条件差的患者使用NP方案,可以更好地控制费用。关键词癌,非小细胞肺;药物疗法;成本-效果中图分类号:R73053文献标识码:A文章编号:1009-6639(2009)07-0595-04ComparisonofFourDifferentCisplatin-basedChemotherapyRegimensforAdvanced
4、Non-smallCellLungCancerWANGHai-yong,PANXi-long(SchoolofPublicHealth,PekingUniversity,Beijing100083,China)AbstractObjectiveTocomparetheeffectivenessandexpensesoffourdifferentCisplatin-basedchemotherapyregimensforadvancednon-smallcelllungcancerMet
5、hodsAtotalof153advancednon-smallcelllungcancercasesweredividedinto4groups:36casesinTPgroup(paclitaxe,lcisplatin),51casesinNPgroup(vinorelbine,cisplatin),39casesinGPgroup(gemcitabine,cisplatin)and27casesinMVPgroup(mitomycin,vindesine,cisplatin)Short-t
6、ermresponsesandexpensesofthechemotherapyregimenswerecomparedbyretrospectiveanalysisandcost-effectivenessanalysisofpharmaco-economics,respectivelyResultsInTP,NP,GPandMVPgroups,theshort-termresponserateswere278%,294%,333%,and222%(P>005);tumorcontr
7、olrateswere750%,686%,897%,and556%(P<005);averagecostswere332043,206083,274390,and120249yuan;C/Eresponserateswere11944,7042,8239,and5416;andC/Eratesoftumorcontrolwere4427,3018,3060and2163,respectivelyConclusionAllthefourcisplatin-base
8、dchemotherapyregimensareeffectiveintreatmentofadvancednon-smallcelllungcancer,andGPregimenhasadvantagesintumorcontrolandlesstoxicandsideeffects,NPregimenismoreoptimalinexpensecontrolGPregimenisrecommendedtoelderlypatientswithgo
